Mikellis stressed that KEFEA’s priorities in the near future will be the implementation of a viable and effective National Health Scheme in Cyprus and the realisation of European directive and falsified medicines. Jacqueline Anastassiades, Managing Director of Merck Sharp & Dohme (MSD) in Cyprus, was elected as vice president. 

KEFEA, founded in 2006, represents the pharmaceutical industry in Cyprus with the aim to implement a sustainable healthcare system for all Cypriots. It’s members are relevant healthcare stakeholders.